DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen Et Al US 2013 02374.39A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen et al. (43) Pub. Date: Sep. 12, 2013 (54) SYSTEMIS AND METHODS USING Publication Classification BOMARKERPANEL, DATA (71) Applicants: Craig M. Stolen, New Brighton, MN (51) Int. Cl. (US); Timothy E. Meyer, North Oaks, GOIN33/68 (2006.01) MN (US); Milan Seth, Minneapolis, MN (52) U.S. Cl. (US); Francis G. Spinale, Blythewood, CPC .................................. G0IN33/6893 (2013.01) SC (US); Nicholas David Wold, Arden USPC .............................................. 506/9; 435/7.92 Hills, MN (US) (72) Inventors: Craig M. Stolen, New Brighton, MN (US); Timothy E. Meyer, North Oaks, (57) ABSTRACT MN (US); Milan Seth, Minneapolis, MN (US); Francis G. Spinale, Blythewood, SC (US); Nicholas David Wold, Arden Embodiments of the disclosure are related to systems and Hills, MN (US) methods for utilizing biomarker panel data with respect to (73) Assignees: MEDICAL UNIVERSITY OF medical devices and methods, amongst other things. In an SOUTH CAROLINA, CHARLESTON, embodiment, the disclosure can include a method of predict SC (US); CARDIAC PACEMAKERS, ing the likelihood of response to CRT therapy. The method INC., ST. PAUL, MN (US) can include quantifying levels of one or more biomarkers in a (21) Appl. No.: 13/756,129 biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of (22) Filed: Jan. 31, 2013 biomarkers includes at least two selected from the group Related U.S. Application Data consisting of CRP, SGP-130, SIL-2R, STNFR-II, IFNg, BNP (60) Provisional application No. 61/593,037, filed on Jan. sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other 31, 2012. embodiments are also included herein. Patent Application Publication Sep. 12, 2013 Sheet 1 of 7 US 2013/02374.39 A1 Quantifying Levels of Biomarkers Analyzing the Quantified Levels FIG. 1 Quantifying Levels Of Biomarkers Placing the Patient into a Category FIG. 2 Patent Application Publication Sep. 12, 2013 Sheet 2 of 7 US 2013/02374.39 A1 Quantifying Levels of Biomarkers Analyzing the Quantified Levels Adjusting Therapy FIG. 3 Patent Application Publication Sep. 12, 2013 Sheet 3 of 7 US 2013/02374.39 A1 350 Patient With DOCumented Heart Failure 352 Curren F Medications and Guideline 354 Met? Biomarker Up-Titrate? Add 368 Panel Medications. Using Analysis AHA IACC Guidelines 370 Follow-Up 372 Up-Tirate HF tandard of 360 Care Met? 358 Medications 362 Schedule Patient for CRT Device Follow-Up Referral for Implant Advanced HF Biomarker Treatment Panel Analysis FIG. 4 Patent Application Publication Sep. 12, 2013 Sheet 4 of 7 US 2013/02374.39 A1 Z2 Patent Application Publication Sep. 12, 2013 Sheet 5 of 7 US 2013/02374.39 A1 0// ?ETTONLNOO 06/G9/09/GG/ èJETTONLNOO G0/ Patent Application Publication Sep. 12, 2013 Sheet 6 of 7 US 2013/02374.39 A1 872 WENTRICULAR CHANNEL INTERFACE MCROPROCESSOR CHANNEL NTERFACE SHOCK PULSE GENERATOR TELEMETRY INTERFACE FIG. 7 US 2013/0237439 A1 Sep. 12, 2013 SYSTEMS AND METHODS USING from the group consisting of CRP, SGP-130, sIL-2R, STNFR BOMARKERPANEL, DATA II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. In some embodiments, the method can include 0001. This application claims the benefit of U.S. Provi quantifying levels of one or more of a panel of biomarkers in sional Application No. 61/593,037, filed Jan. 31, 2012, the a biological sample of a patient, and using the quantified content of which is herein incorporated by reference in its levels to place the patient into one of a set of categories, the set entirety. of categories including CRT therapy responders, wherein the panel of biomarkers includes at least two selected from the TECHNICAL FIELD group consisting of CRP, SGP-130, SIL-2R, STNFR-II, IFN 0002 This disclosure relates generally to medical devices y, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. and methods, and more particularly, to systems and methods 0008. An embodiment can include a method of identifying for utilizing biomarker panel data with respect to medical patients that are unlikely to respond to CRT therapy. The devices and methods, amongst other things. method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient, and BACKGROUND OF THE INVENTION analyzing the quantified levels to determine likelihood of 0003 Implantable medical devices (IMDs) are commonly response to CRT therapy, wherein the panel of biomarkers used to provide treatment to patients. Some types of implant includes at least two selected from the group consisting of able medical devices deliver electrical stimuli to a target CRP, SGP-130, sIL-2R, STNFR-II, IFNg, BNP, sST2, MMP tissue via a lead wire (“stimulation lead') or catheter having 2, MMP-9, TIMP-1, TIMP-2, TIMP-4. one or more electrodes disposed in or about the target tissue. 0009. An embodiment can include a method of determin In the context of cardiac rhythm management devices, the ing prognosis of a patient receiving CRT therapy. The method electrical stimulican be delivered in the form of pacing pulses can include selecting a patient that is receiving CRT therapy, to pace the heart and/or relatively high energy defibrillation quantifying levels of one or more of a panel of biomarkers in shocks or cardioversion shocks to terminate arrhythmias. a biological sample of the patient, and analyzing the quanti 0004. The American College of Cardiology/American fied levels to determine prognosis, wherein the panel of biom Heart Association Guidelines for the Evaluation and Manage arkers includes at least two selected from the group consisting ment of Chronic Heart Failure in the Adult defines heart of CRP, SGP-130, sIL-2R, STNFR-II, IFNg, BNP sST2, failure as a “complex clinical syndrome that can result from MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. any structural or functional cardiac disorder that impairs the 0010. An embodiment can include a method of treating a ability of the ventricle to fill with oreject blood'. Heart failure patient. The method can include quantifying levels of one or has various adverse hemodynamic and circulatory conse more of a panel of biomarkers in a biological sample of the quences. Signs and symptoms of heart failure include sys patient, analyzing the quantified levels, and adjusting therapy temic and pulmonary fluid accumulation, reduced activity for the patient based at least in part on the analysis results, levels and exercise tolerance, and poor kidney and cerebral/ wherein the panel of biomarkers includes at least two selected cognitive function, amongst others. Over time, patients with from the group consisting of CRP, SGP-130, sIL-2R, STNFR heart failure typically experience further declines in cardiac II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, pump function which is accompanied by increased fluid accu TIMP-4. In some embodiments, the method can include mulation, continued decline in activity/exercise tolerance, selecting a patient that is receiving CRT therapy, quantifying further decline in kidney and cerebral/cognitive function. levels of one or more of a panel of biomarkers in a biological 0005 Cardiac resynchronization therapy (CRT) is used to sample of the patient, analyzing the quantified levels to deter treat the delay in ventricular contractions of the heart that mine an expected response to CRT therapy, comparing the occur in some people with advanced heart failure. A delay expected response to CRT therapy to the patient’s actual between the contraction of the right and left ventricles often response to CRT therapy, and adjusting parameters of the occurs with heart failure, leading to biomechanically ineffi CRT therapy if the patients actual response to CRT therapy is cient heart contractions and reduced cardiac output. Cardiac worse than the expected response to CRT therapy, wherein the resynchronization therapy aims to address this problem panel of biomarkers includes at least two selected from the through stimulation of multiple chambers of the heart in order group consisting of CRP, SGP-130, SIL-2R, STNFR-II, IFNg, to resynchronize contraction of the right and left ventricles. BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. 0006 Biomarkers, or biological markers, are substances 0011. An embodiment can include a method of monitoring that can be used as an indicator of a biological state. Biom a patient receiving CRT therapy. The method can include arkers can include Small molecules, proteins, nucleic acids, quantifying levels of one or more of a panel of biomarkers in carbohydrates, lipids, and combinations thereof. a biological sample of the patient, and analyzing the quanti fied levels to determine status. In some embodiments the SUMMARY OF THE INVENTION method can include quantifying levels of one or more of a 0007 Embodiments of the disclosure are related to sys panel of biomarkers in a biological sample of the patient, and tems and methods for utilizing biomarker panel data and analyzing the change in quantified levels overtime to perform related medical devices and methods, amongst other things. one or more selected from the group consisting of analyzing An embodiment can include a method of predicting the like response to therapy changes and monitoring disease progres lihood of response to CRT therapy. The method can include S1O. quantifying levels of one or more of a panel of biomarkers in 0012. An embodiment can include an assay kit including a biological sample of a patient, analyzing the quantified probes to quantify levels of one or more of a panel of biom levels to determine likelihood of response to CRT therapy, arkers in a biological sample of a patient, wherein the panel of wherein the panel of biomarkers includes at least two selected biomarkers includes at least two selected from the group US 2013/0237439 A1 Sep.
Load more

Recommended publications
  • Study Protocol: Amendment 3
    (!') GILEAU CLINICAL STUDY PROTOCOL Study Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Unu·eated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-fmding, Lead-in Phase Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA IND Number: 120605 EudraCT Number: 2014-004480-20 ClinicalTrials.gov Identifier: NCT021 01021 Indication: Previously unu·eated metastatic pancreatic ductal adenocarcinoma Protocol ID: GS-US-370-1296 Clinical Trials Manager: Name: PPD Telephone: PPD Gilead Medical Monitor: Name: Peter Lee, MD, PhD Telephone: PPD Clinical Program Manager: Name: PPD Telephone: PPD Protocol Version/Date: Original: 11 Febmary 2014 Amendment 1: 14 March 2014 Amendment 2: 25 August 2014 Amendment 3: 16 July 2015 CONFIDENTIALITY STATEMENT The inf01mation contained in this document, pruiicularly unpublished data, is the prope1iy or under conu·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The infonnation is only to be used by you in connection with authorized clinical studies of the investigational dmg described in the protocol. You will not disclose any of the infonnation to others without written authorization from Gilead Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those persons
    [Show full text]
  • Abstract Supplement
    2018 ABSTRACT SUPPLEMENT SAN FRANCISCO June 20-23 • Marriott Marquis Federation of Clinical Immunology Societies June 20-23, 2018 San Francisco, California FOCIS 2018 Abstract Supplement TABLE OF CONTENTS Abstracts by Subject Area …………………………………………………………...……………………………….2 Allergy/asthma ……………………………………………………………………………………………………...2 Autoimmune neurologic diseases .............................................................................................................. 7 Autoimmune rheumatologic diseases ...................................................................................................... 19 Bone marrow or stem cell transplantation ............................................................................................... 37 Cytokines/chemokines ............................................................................................................................ 42 Diabetes and other autoimmune endocrine diseases .............................................................................. 47 General Autoimmunity…………………………………………………………………………………………….58 Genetics .................................................................................................................................................. 70 Immune monitoring .................................................................................................................................. 74 Immunity & infection ................................................................................................................................ 82 Immunodeficiency:
    [Show full text]
  • Granulocyte Colony-Stimulating Factor (G-CSF)
    British Journal of Cancer (1999) 80(1/2), 229–235 © 1999 Cancer Research Campaign Article no. bjoc.1998.0344 Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response E Reyes1, I García-Castro2, F Esquivel1, J Hornedo2, H Cortes-Funes2, J Solovera3 and M Alvarez-Mon1 1Medicine/Immune System Diseases Oncology Service, Department of Medicine ‘Principe de Asturias’ University Hospital, Alcalá University, Carretera Madrid- Barcelona, Km 33.600, 28871 Alcalá de Henares, Madrid, Spain; 2Medical Oncology Department, ‘12 de Octubre’ University Hospital, Madrid, Spain; 3Amgen, S.A. Barcelona, Spain Summary Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production.
    [Show full text]
  • Cytokines As Cellular Pathophysiology of Many Diseases
    Review Mediators of Inflammation, 5, 417-423 (1996) CYTOKINES and their receptors are involved in the Cytokines as cellular pathophysiology of many diseases. Here we pre- sent a detailed review on cytokines, receptors and communicators signalling routes, and show that one important lesson from cytokine biology is the complex and diverse regulation of cytokine activity. The activ- cA ity of cytokines is controlled at the level of trans- R. Debets and H. F. J. Savelkoul cription, translation, storage, processing, post- translational modification, trapping, binding by soluble proteins, and receptor number and/or Department of Immunology, Erasmus University, function. Translation of this diverse regulation in P.O. Box 1738, 3000 DR Rotterdam, The Netherlands strategies aimed at the control of cytokine activity will result in the development of more specific and selective drugs to treat diseases. CACorresponding Author Key words: Control of activity, Cytokine, Interference in cytokine activity, Receptor, Signalling routes Introduction lation and act locally to restore homeostasis. Cytokines bind with high affinity to specific For over two decades, it has been recognized receptors on the surface of target cells. When that immune-competent cells produce peptide cytokine receptors are expressed on the cyto- mediators, now termed cytokines. Cytokines act kine-producing cell, autocrine cellular activation as chemical communicators between cells, but may be the result. If the receptor is expressed mostly not as effector molecules in their own on a neighbouring cell, binding may result in right. The biological function of many cytokines paracrine cytokine activation. These features is mediated through their ability to regulate could explain the sometimes high local concen- gene expression in target cells.
    [Show full text]
  • Following High-Dose Chemotherapy and Autologous Bone Marrow Transplantation
    Bone Marrow Transplantation, (1997) 19, 315–322 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 A phase I trial of recombinant human interleukin-1b (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation M Elkordy, M Crump, JJ Vredenburgh, WP Petros, A Hussein, P Rubin, M Ross, C Gilbert, C Modlin, B Meisenberg, D Coniglio, J Rabinowitz, M Laughlin, J Kurtzberg and WP Peters Duke University, Bone Marrow Transplant Program, Durham, NC, USA Summary: The use of lineage-specific hematopoietic growth factors such as GM-CSF and G-CSF shortens the duration of neu- We studied the effects of escalating doses of recombi- tropenia following high-dose chemotherapy and ABMT.1–3 nant human IL-1b in patients receiving high-dose Recently with molecular cloning much interest has emerged chemotherapy and ABMT for metastatic breast cancer in the use of growth factors, which have multilineage pro- or malignant melanoma. Sixteen patients received IL- liferative effects, to shorten the duration of neutropenia and 1b, 4 to 32 ng/kg/day administered subcutaneously for platelet transfusion-dependence and to decrease the number 7 days beginning 3 h after bone marrow infusion. Three of red blood cell transfusions.4 patients at the highest dose level also received G-CSF IL-1b is a polypeptide which exerts effects on hemato- following completion of IL-1b. All patients completed poiesis through several mechanisms, and produces a broad the 7 days of therapy. The majority of patients experi- spectrum of metabolic, immunologic and inflammatory enced chills and fever following one or more injections, effects.5,6 In addition to having a direct stimulatory effect and seven had severe pain at the injection site.
    [Show full text]
  • The Immunomodulatory Impact of Multipotential Stromal Cells on Monocytes in Healthy People and Patients with Rheumatoid Arthritis
    The immunomodulatory impact of multipotential stromal cells on monocytes in healthy people and patients with rheumatoid arthritis Priyanka Dutta Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds Faculty of Medicine and Health School of Medicine September 2020 Primary Supervisor: Professor Michael McDermott Secondary Supervisor: Dr Elena Jones Secondary Supervisor: Professor Graham Cook The candidate confirms that the work submitted is her own work and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and no quotation from the thesis may be published without proper acknowledgement. The right of Priyanka Dutta to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. i Acknowledgements I would like to express my deep gratitude to my supervisors Professor Michael McDermott, Dr Elena Jones and Professor Graham Cook for providing me with this opportunity. Thank you for all your understanding, guidance and immense support inside and outside of the lab. Thanks for sharing your knowledge and ideas to support this PhD work, most of all thank you for your patience. Also, thanks to Chi Wong, Rekha Parmar, Adam Davidson and Elizabeth Straszynski for their great support in the lab, as well as the staff and patients at Chapel Allerton Hospital for providing patient samples. Thank you to Professor Paul Genever for providing the Y201 and Y202 MSC immortalised cell lines and to Dr Andreia Riberio and Professor Rhodri for their expert advice on optimisation of the whole blood assay.
    [Show full text]
  • Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications
    Review Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications Pushpalatha Palle 1,2,†, Kelly L. Monaghan 1,2,†, Sarah M. Milne 1,2 and Edwin C.K. Wan 1,2,* 1 Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA; [email protected] (P.P.); [email protected] (K.L.M.); [email protected] (S.M.M.) 2 Center for Basic and Translational Stroke Research and the Center for Neurodegenerative Diseases, Blanchette Rockefeller Neurosciences Institute, West Virginia University School of Medicine, Morgantown, WV 26506, USA * Correspondence: [email protected]; Tel.: +1‐304‐263‐6293; Fax: +1‐304‐293‐7823 † These authors contributed equally to this work. Received: 22 August 2017; Accepted: 11 October 2017; Published: 13 October 2017 Abstract: Multiple sclerosis (MS) is one of the most common neurological disorders in young adults. The etiology of MS is not known but it is widely accepted that it is autoimmune in nature. Disease onset is believed to be initiated by the activation of CD4+ T cells that target autoantigens of the central nervous system (CNS) and their infiltration into the CNS, followed by the expansion of local and infiltrated peripheral effector myeloid cells that create an inflammatory milieu within the CNS, which ultimately lead to tissue damage and demyelination. Clinical studies have shown that progression of MS correlates with the abnormal expression of certain cytokines. The use of experimental autoimmune encephalomyelitis (EAE) model further delineates the role of these cytokines in neuroinflammation and the therapeutic potential of manipulating their biological activity in vivo.
    [Show full text]
  • An Emerging Role for the Anti-Inflammatory Cytokine
    Tsai et al. Journal of Biomedical Science 2013, 20:40 http://www.jbiomedsci.com/content/20/1/40 REVIEW Open Access An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection Tsung-Ting Tsai1,2, Yi-Jui Chuang2,3, Yee-Shin Lin1,3,4, Shu-Wen Wan3,4, Chia-Ling Chen3,4 and Chiou-Feng Lin1,2,3,4* Abstract Infection with dengue virus (DENV) causes both mild dengue fever and severe dengue diseases, such as dengue hemorrhagic fever and dengue shock syndrome. The pathogenic mechanisms for DENV are complicated, involving viral cytotoxicity, immunopathogenesis, autoimmunity, and underlying host diseases. Viral load correlates with disease severity, while the antibody-dependent enhancement of infection largely determines the secondary effects of DENV infection. Epidemiological and experimental studies have revealed an association between the plasma levels of interleukin (IL)-10, which is the master anti-inflammatory cytokine, and disease severity in patients with DENV infection. Based on current knowledge of IL-10-mediated immune regulation during infection, researchers speculate an emerging role for IL-10 in clinical disease prognosis and dengue pathogenesis. However, the regulation of dengue pathogenesis has not been fully elucidated. This review article discusses the regulation and implications of IL-10 in DENV infection. For future strategies against DENV infection, manipulating IL-10 may be an effective antiviral treatment in addition to the development of a safe dengue vaccine. Keywords: DENV, Antibody-dependent
    [Show full text]
  • Hematologie 2021 POST-ASH
    ONLINE 21. PRAŽSKÉ HEMATOLOGICKÉ DNY Hematologie 2021 POST-ASH KAM NÁS POSOUVÁ TO NEJLEPŠÍ Z LOŇSKÉ SVĚTOVÉ HEMATOLOGIE 28. – 29. 1. 2021 Clarion Congress Hotel Prague (Freyova 33, Praha 9 – Vysočany) PROGRAM KONFERENCE A SBORNÍK ABSTRAKTŮ 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 OBSAH 2 POST-ASH OBSAH 2 ÚVODNÍ SLOVO 3 DŮLEŽITÉ INFORMACE 4 SCHÉMA ODBORNÉHO PROGRAMU 6 PODROBNÝ PROGRAM KONFERENCE 7 POSTEROVÁ SEKCE 11 OŠETŘOVATELSKÝ PROGRAM 16 SATELITNÍ SYMPOZIA 18 SBORNÍK ABSTRAKTŮ 25 ABECEDNÍ REJSTŘÍK AUTORŮ 119 PŘEHLED PARTNERŮ A VYSTAVOVATELŮ 122 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 ÚVODNÍ SLOVO 3 POST-ASH Vážené kolegyně, vážení kolegové, milí hosté 21 pražských hematologických dnů-HEMATOLOGIE 2021, loni jsme na 20 pražských hematologických dnech zahájili novou tradici, kterou účastníci velmi přivítali: uspořádat konferenci na začátku roku a reflektovat při nich to nejlepší, co se v našem oboru odehrálo na loňských světových kongresech Jsou to především ASH a EHA, ale i více specializované konference I když celý loňský rok poznamenala pandemie, bylo nám celou dobu jasné, že úspěšnou tradici nesmíme přerušit Optimisté v našich řadách doufali, že se podaří uspořádat konferenci v klasickém formátu, nicméně připravovali jsme paralelně všechny varianty Nakonec zvítězila varianta výhradně online Podobně jako našim dětem chybí interakce se spolužáky, i my budeme postrádat milá setkání s kolegy, hovory ve frontě na kávu, diskusi v přednáškových sálech i chutný štrůdl v hotelu
    [Show full text]
  • Effects of Biological Therapies on Molecular Features of Rheumatoid
    International Journal of Molecular Sciences Review Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis , Chary Lopez-Pedrera * y , Nuria Barbarroja y, Alejandra M. Patiño-Trives, Maria Luque-Tévar, Eduardo Collantes-Estevez , Alejandro Escudero-Contreras z and Carlos Pérez-Sánchez z Rheumatology Service, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, E-14004 Córdoba, Spain; [email protected] (N.B.); [email protected] (A.M.P.-T.); [email protected] (M.L.-T.); [email protected] (E.C.-E.); [email protected] (A.E.-C.); [email protected] (C.P.-S.) * Correspondence: [email protected] or [email protected]; Tel.: +34-957-213-795 These authors shared first authorship. y These authors shared last authorship. z Received: 31 October 2020; Accepted: 27 November 2020; Published: 28 November 2020 Abstract: Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients.
    [Show full text]
  • WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 1/36 (2006.01) A61K 38/19 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/28 (2006.01) A61M 1/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, PCT/IB2013/001583 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 3 1 May 2013 (3 1.05.2013) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, PCT/EP20 12/002340 1 June 2012 (01 .06.2012) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 12196527.
    [Show full text]
  • Subunit Α Receptor Shedding of the Cell Surface GM-CSF Monocytes
    Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human This information is current as Monocytes: Evidence for Ectodomain of September 25, 2021. Shedding of the Cell Surface GM-CSF Receptor α Subunit Jay M. Prevost, Jennifer L. Pelley, Weibin Zhu, Gianni E. D'Egidio, Paul P. Beaudry, Carin Pihl, Graham G. Neely, Downloaded from Emmanuel Claret, John Wijdenes and Christopher B. Brown J Immunol 2002; 169:5679-5688; ; doi: 10.4049/jimmunol.169.10.5679 http://www.jimmunol.org/content/169/10/5679 http://www.jimmunol.org/ References This article cites 39 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/169/10/5679.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor ␣ Subunit1 Jay M.
    [Show full text]